This is a randomized, double-blind, crossover study in healthy adult subjects. Each subject will receive a single dose of bisoprolol 5 mg p.o. and nebivolol 5 mg p.o. with 1 week washout period. All subjects will undergo a physical examination, 12-lead electrocardiography and a comprehensive echocardiographic study before the administration of the study drug and 5 hours thereafter.

开始日期2030-01-01

申办/合作机构-

NCT05880056 / Not yet recruiting临床4期

A Prospective, Multicenter, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension

The trial is designed to assess the safety and investigation of the efficacy of a single oral dose of bisoprolol (Nerkardou - Nerhadou) oral dissolvable film (ODF) 5 & 10 mg, and patients' compliance in the treatment of essential hypertension. This is a Phase IV, open-label, single-arm, prospective trial where subjects will receive:
1. Bisoprolol (Nerkardou) at an initial dose of 5 (mg) milligrams once daily for 2 weeks.
2. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then the dose will be titrated to 10 mg once daily (non-responders). Dose-Titration will be done at any follow-up visit based on the response.
3. The total duration of study treatment will be 12 weeks ±2 days, and the total sample size of the study will be 406 participants.

开始日期2024-05-21

申办/合作机构

GRC

[+1]

IRCT20220211053992N27 / Suspended

In vivo Bioequivalence study of Bisoprolol H (10/25) tablet manufactured by AaniDarman Pharmaceutical Co. Compared to innovator Product

开始日期2024-04-13

申办/合作机构

Tabriz University of Medical Sciences

100 项与比索洛尔相关的临床结果

登录后查看更多信息

100 项与比索洛尔相关的转化医学

登录后查看更多信息

100 项与比索洛尔相关的专利（医药）

登录后查看更多信息

1,805

项与比索洛尔相关的文献（医药）

2024-05-01·Current Drug Safety

Immediate Reaction to Propranolol: An Extremely Rare but Important Condition. A Case Report

作者: Sánchez-González, María-José ; Monjo-Paz, Josefa ; Alvarez-Mon, Melchor ; González-Bravo, Lucía ; Barbarroja-Escudero, José ; Matas-Dominguez, Dorotea

Introduction::

Beta-blockers involve a group of drugs widely used nowadays. Propranolol was the first beta-blocker available in the market. It is the most prescribed first-generation betablocker and is commonly used. Beta-blocker allergy is extremely unusual. Only an isolated case of an urticaria reaction to propranolol has been published in 1975.

Case Presentation::

We present a 44-year-old man. In 2016, he was treated with a daily dose of 5 mg of propranolol prescribed for a diagnosis of essential tremor. On the third day of medical treatment, he experienced an episode of generalized urticaria directly related to the administration of propranolol. He continued with his habitual treatment and he had no other urticaria episodes. A drug provocation test was carried out with gradually increasing doses of the culprit drug. Thirty minutes after a total cumulative dose of 5 mg, the patient had several hives on the chest, abdominal region and arms. Two weeks later, a new drug provocation test was performed to bisoprolol as an alternative beta-blocker, with good tolerance.

Conclusion::

We describe a new case of urticaria secondary to propranolol, presenting as an immediate hypersensitivity reaction. Bisoprolol has been succesfully proved to be a safe option. Bisoprolol is a second-generation beta-blocker, it is available and commercialized worldwide, which makes it a good alternative.

2024-02-01·Heart

Management of arrhythmogenic right ventricular cardiomyopathy

Review

作者: Elliott, Perry M ; Al-Aidarous, Sayed ; Lambiase, Pier D ; Protonotarios, Alexandros

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Treating this condition can be challenging due to progressive fibrosis, phenotypic variations and small patient cohorts limiting the feasibility of conducting meaningful clinical trials. Although widely used, the evidence base for anti-arrhythmic drugs is limited. Beta-blockers are theoretically sound, yet their efficacy in reducing arrhythmic risk is not robust. Additionally, the impact of sotalol and amiodarone is inconsistent with studies reporting contradictory results. Emerging evidence suggests that combining flecainide and bisoprolol may be efficacious.Radiofrequency ablation has shown some potential in disrupting ventricular tachycardia circuits, with combined endo and epicardial ablation yielding better results which could be considered at the index procedure. In addition, stereotactic radiotherapy may be a future option that can decrease arrhythmias beyond simple scar formation by altering levels of Nav1.5 channels, Connexin 43 and Wnt signalling, potentially modifying myocardial fibrosis.Future therapies, such as adenoviruses and GSk3b modulation, are still in early-stage research. While implantable cardioverter-defibrillator implantation is a key intervention for reducing arrhythmic death, the risks of inappropriate shocks and device complications must be carefully considered.

2024-01-26·Medicine

Presentation of glomerulocystic disease in a young onset diabetes: A case report

Article

作者: Weng, Cheng-Hao ; Hsu, Ching-Wei ; Huang, Wen-Hung ; Tu, Kun-Hua ; Chen, Tai-Di

Rationale::

This case report presents a challenging medical scenario involving a young adult male who exhibited an unusual combination of symptoms, including abrupt weight loss, declining renal function, proteinuria, and concurrent onset of diabetes mellitus. Remarkably, the patient had no previous medical history or family history of similar conditions, necessitating a comprehensive investigation.

Patient Concerns::

On March 10, 2021, a 25-year-old male sought medical attention due to the aforementioned symptoms. Initial assessments revealed stage 5 chronic kidney disease, with elevated blood urea nitrogen (BUN) and serum creatinine (Cr) levels, as well as significant proteinuria. The only notable physical finding was obesity, and renal ultrasound showed normal-sized kidneys without cysts.

Diagnosis::

A treatment plan was initiated to stabilize creatinine levels, including medications such as Glimepiride, Glyxambi, Bisoprolol, Amlodipine, and Valsartan. However, despite diligent medication management, proteinuria persisted, prompting further evaluation. A renal biopsy was performed on April 12th, 2023, leading to the diagnosis of glomerulocystic kidney disease with early-stage changes indicative of diabetic nephropathy.

Interventions::

The patient continues to receive ongoing care and follow-up at our outpatient clinic to optimize therapeutic interventions and elucidate the underlying etiology of this complex clinical scenario.

Outcomes::

Ongoing investigations and therapeutic interventions are crucial to understand the underlying cause and optimize patient care in this intricate clinical scenario.

Lessons::

This case underscores the complexity of diagnosing and managing a young adult presenting with concurrent renal dysfunction, proteinuria, and diabetes mellitus in the absence of prior underlying conditions. It highlights the importance of comprehensive evaluation and ongoing care in such challenging cases.

项与比索洛尔相关的新闻（医药）

2024-04-08

·Science Daily

Unnecessary use of beta-blockers after a heart attack?

Half of all patients discharged from hospital after a heart attack are treated with beta-blockers unnecessarily, new study suggests. Half of all patients discharged from hospital after a heart attack are treated with beta-blockers unnecessarily. This is according to a new study published in the New England Journal of Medicine. "I am convinced that this will influence future practice," says Tomas Jernberg, Professor at Karolinska Institutet and lead researcher of the study. Today, when patients are discharged from hospitals after an acute heart attack, they are regularly treated with beta-blocker drugs such as metoprolol and bisoprolol. Now new research shows that about half of them do not benefit from the treatment and should not receive it at all. These are the patients who have suffered a small heart attack and have retained heart function afterwards. The study will change the way patients are treated in the future, says the lead researcher and last author of the study, Professor Tomas Jernberg from the Department of Clinical Sciences at Karolinska Institutet. "I am convinced that this will influence future practice. This study has already been mentioned in the European guidelines for cardiac care, so the results are in demand," he says. The project was led by researchers at Karolinska Institutet, Lund University and Uppsala University. More than 5,000 patients at 45 hospitals in Sweden, Estonia and New Zealand who suffered a small heart attack were randomized to either receive or not receive beta-blockers at discharge. The study began in September 2017 and patients were followed up until November 2023, by which time 7.9 percent of those receiving beta-blockers had the primary outcome of death or a new heart attack, compared to 8.3 percent of those not receiving beta-blockers. This difference is not statistically significant. Nor was there any difference between the groups in the secondary outcomes. The result means that, unusually, the drug treatment becomes simpler and cheaper for all parties, says Tomas Jernberg. "Typically, new research results in the addition of a medication to a patient's regimen. However, this study shows that patients will benefit from taking one fewer drug." " But he immediately warns patients not to stop their treatment on their own accord. The current study is only about the effect of starting treatment after a small heart attack, not after a larger one. Nor does it show anything about the effects of stopping treatment. More importantly, stopping medication should always be done in consultation with the treating physician. "This is for several reasons. There may be other causes, other diagnoses, behind the use of beta-blockers. Then there is the fact that if you are going to stop, you should stop beta-blockers gradually. If you do it too quickly, you can get some heart palpitations and other discomfort. So, it is very important that you talk to your doctor before stopping any heart medication," says Tomas Jernberg. The research was funded by the Swedish Research Council and the Swedish Heart-Lung Foundation. The researchers report that there are no conflicts of interest. Facts: In Sweden, around 20,000 people have a heart attack every year. Half of them have a small heart attack with retained heart function afterward. This means that the heart can still pump out more than 50 percent of the volume in the left chamber of the heart, known as preserved left ventricular systolic function. The reasons behind the current practice of giving everyone a beta-blocker after a heart attack can be traced back to the 1980s when studies showed unequivocally that it was beneficial. But since then, other cardiovascular treatments have improved, as have diagnostics, so doctors are now detecting many of the heart attacks that were never classified as infarctions before. This, together with the fact that the incidence of heart attacks has steadily declined since the 1980s, means that today's heart attacks are generally smaller and with a higher proportion of people with preserved left ventricular function.

AHA会议

2024-01-23

·奇点网

精神疾病可能已经成为先天性心脏病患者所面临的最常见合并症，需要得到重视。

*仅供医学专业人士阅读参考先天性心脏病（CHD）是最常见的先天性畸形类型之一，近年来的研究显示，CHD在新生儿中的患病率为9.4/1000人[1]。随着诊疗技术的进步，CHD患儿的死亡率显著下降，生存期显著延长，超过90%的CHB患儿能够活到成年[2]。荷兰的国家CONCOR登记处数据显示，接受过手术的轻度CHD患者的预期寿命与一般人群相似（中位生存期为84.1年），中度或重度患者会有相应的缩短（中位生存期分别为75.4年和53.4年）[3]。加拿大魁北克省的CHD数据库也显示，2010年时，所有登记在册的CHD患者中，已有66%为成年患者[4]。随着年龄的增加，CHD患者的疾病负担从心脏转移到获得性心血管和全身并发症，这使得他们需要面对高昂的社会成本，不仅仅是医疗保健方面，还有生活质量，与健康的同龄人相比，CHD患者更容易遭受心理困扰。目前，已有许多研究开始关注成年CHD患者的精神健康和生活质量，希望进一步提高他们的健康寿命。最近，《美国心脏病学会杂志》上发表了一项新的研究结果，国际成人先天性心脏病学会的研究小组基于对15个国家和地区近4000名成年CHD患者的调查，揭示了30%的患者存在抑郁和/或焦虑症状，与较差的生活质量和健康状况相关[5]。这项研究是成人先天性心脏病患者报告结局评估模式-国际研究（APPROACH-IS）的子研究，纳入了3815例成年CHD患者，不包含特发性肺动脉高压患者或接受过心脏移植的患者，来自阿根廷、澳大利亚、比利时、加拿大、法国、印度、意大利、日本、马耳他、挪威、瑞典、瑞士、中国台湾、荷兰和美国。参与者的平均年龄为34.8±12.9岁，其中52.7%为女性，352例参与者的病历中有情绪和/或焦虑障碍记录。研究人员使用医院焦虑和抑郁量表（HADS）评估参与者的焦虑症状（HADS-A）和抑郁症状（HADS-D），每个评估包含7项，每项分数为0-3，总分为0-21，≥8分表示存在明显症状，8-10分为轻度，11-13分为中度，≥14分为重度。使用生活质量线性模拟量表（QoL-LAS）和EuroQoL-5D视觉模拟量表-健康状况（HS-VAS）评估生活质量和健康状况，总分为0-100，评分越高结果越好。参与者的平均HADS-A评分为5.6±3.9，高于HADS-D的3.2±3.3，中位评分结果也是相似的。3815例参与者中，1148例（30.1%）在至少1个量表的评估中表现出明显症状，其中18.3%仅表现出焦虑症状，2.9%仅表现出抑郁症状，二者都有的为8.9%。按照国家/地区划分，表现出焦虑症状的比例介于荷兰的12.9%和法国的38.2%之间，抑郁症状的比例介于挪威的6.5%和日本的21.2%之间。总体，及各国家和地区参与者的焦虑（蓝）和抑郁（红）症状的比例多变量校正风险模型中，与焦虑症状有关的因素包括年龄较小、女性、无业或学生（与全职或兼职工作相比），以及NYHA心脏功能分级较高（心脏功能差），与抑郁症状有关的因素包括年龄较大、女性、无业和NYHA心脏功能分级较高。与焦虑和抑郁症状有关的因素研究人员最后比较了经HADS评估的无明显症状、轻度、中度和重度4类参与者的生活质量和健康状况的差异。无论是HADS-A还是HADS-D，它们评定的症状等级均与QoL-LAS和HS-VAS评分呈反比，即症状越严重，生活质量和健康状况越差。这项研究是迄今规模最大的评估成年CHD患者心理困扰情况的研究，在这项研究中，近1/3的参与者报告了出现明显的抑郁和/或焦虑症状，对生活质量和健康状况造成了不良影响。研究还提供了与抑郁和焦虑症状有关的风险因素。这些结果为在临床环境中加强识别和管理精神类合并症提供了参考。研究人员指出，正如美国心脏协会此前发表的声明中所指出的，精神疾病可能是CHD患者所面临的最常见的合并症，因此，从意识到这一点到尽快实施预防和干预策略的转换是必要的，应将精神健康专业人士纳入CHD管理的团队中，探索合适的综合管理模式。参考文献：[1] Liu Y, Chen S, Zühlke L, et al. Global birth prevalence of congenital heart defects 1970–2017: updated systematic review and meta-analysis of 260 studies[J]. International journal of epidemiology, 2019, 48(2): 455-463.[2] Marelli A J, Mackie A S, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution[J]. Circulation, 2007, 115(2): 163-172.[3] van der Bom T, Mulder B J M, Meijboom F J, et al. Contemporary survival of adults with congenital heart disease[J]. Heart, 2015, 101: 1989-1995.[4] Marelli A J, Ionescu-Ittu R, Mackie A S, et al. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010[J]. Circulation, 2014, 130(9): 749-756.[5] Kovacs A H, Luyckx K, Thomet C, et al. Anxiety and depression in adults with congenital heart disease[J]. Journal of the American College of Cardiology, 2024, 83(3): 430-441.本文作者丨应雨妍

临床结果

2023-08-21

·Pharmaceutical Technology

Calliditas inches closer to full approval for IgA nephropathy drug

Akosua Mireku @AkosuaMireku1 IgA nephropathy is a kidney disorder that causes inflammation. The US Food and Drug Administration (FDA) has granted Calliditas Therapeutics’ immunoglobulin A (IgA) nephropathy (IgAN) drug Tarpeyo (budesonide) a priority review for a decision on granting it a “full approval”. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. Submit Country Code UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report. The FDA previously granted the drug accelerated approval as the first therapy for the treatment of IgAN, in December 2021. The agency has now set a prescription drug user fee act (PDUFA) date for this supplemental new drug application (sNDA) application of 20 December 2023. Recommended Reports Reports LOA and PTSR Model - Deutetrabenazine in Dyskinesia GlobalData Reports LOA and PTSR Model - (amlodipine + bisoprolol + indapamide + perindopril) GlobalData View all The FDA accepted Calliditas’s sNDA for the drug based on the full data set from the Phase III NefIgArd clinical study (NCT03643965). Patients treated for nine months with Tarpeyo showed a significant reduction of approximately 30%, in the urine protein-to-creatinine ratio compared with the placebo group. The trial also met its primary endpoint of estimated glomerular filtration rate (eGFR), as the therapy demonstrated a significant kidney protective effect over the placebo. Tarpeyo is an oral glucocorticoid anti-inflammatory agent that suppresses the gut immune system. This allows the drug to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. The drug was previously being developed under the brand name Nefecon, with the company renaming the novel targeted-release formulation of the drug as Tarpeyo. This formulation comprises a 4mg enteric-coated capsule, designed to remain intact until it reaches the patient’s ileum. In the 18 August press release announcing the priority review, Calliditas’ CEO Renee Aguiar-Lucander said: “The significant eGFR treatment benefit observed across the entire study population provides further evidence that TARPEYO can be disease-modifying, potentially significantly delaying the need for dialysis or kidney transplantation for patients at risk.” IgAN is a kidney disorder caused by a build-up of antibodies in the kidney tissue. This can cause the kidneys to gradually fail, requiring some patients to undergo dialysis, or in severe cases, kidney transplants. The condition mostly develops between the late teens and late 30s. Calliditas is also working with its European partner, STADA Arzneimettel, to push a European Commission approval of the drug under the brand name Kinpeygo, following its 2022 European conditional authorisation . The Sweden-headquartered company also received conditional approval for the treatment from the UK’s Medicines and healthcare products regulatory agency (MHRA) in February 2023. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country Code UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report.

临床结果临床3期上市批准优先审批加速审批

100 项与比索洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C07AB07	DB00612

研发状态

适应症	最高研发状态	国家/地区	公司
心房颤动	批准上市	日本更多	TOA Eiyo Ltd. 更多
原发性高血压	批准上市	日本更多	TOA Eiyo Ltd. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2021	N/A	高血压	200	Bisoprolol 5 mg	鹽獵鑰鹽膚鑰範餘齋衊(襯齋簾鹹齋餘鹹窪糧鬱) = 選繭顧餘鹹壓積膚顧顧膚膚積蓋鬱醖壓鏇蓋繭 (鬱簾憲餘觸遞製鑰顧淵 ) 更多	-	2021-08-27
				Metoprolol-SR 50 mg	鹽獵鑰鹽膚鑰範餘齋衊(襯齋簾鹹齋餘鹹窪糧鬱) = 簾顧鹹顧憲願蓋夢膚衊膚膚積蓋鬱醖壓鏇蓋繭 (鬱簾憲餘觸遞製鑰顧淵 ) 更多
NCT02391337 (CTgov)	临床4期	心房颤动	161	Bisoprolol (Beta-blocker)	獵餘積衊壓繭餘鏇窪餘(積選艱鏇夢憲齋鬱顧製) = 醖鹹鑰網壓選獵醖選選網網築餘糧製遞繭簾壓 (鹹構顧窪廠廠繭蓋範鏇, 壓顧醖鬱醖鹹蓋窪製膚 ~ 憲壓觸窪襯獵襯積鏇艱) 更多	-	2021-06-16
				digoxin (Digoxin)	獵餘積衊壓繭餘鏇窪餘(積選艱鏇夢憲齋鬱顧製) = 蓋簾壓壓齋廠餘願願願網網築餘糧製遞繭簾壓 (鹹構顧窪廠廠繭蓋範鏇, 獵窪網築顧醖艱襯膚憲 ~ 網淵繭簾築願鏇夢積繭) 更多
NCT03026088 (CTgov)	临床4期	慢性心力衰竭	20	Bisoprolol	鬱膚積鹽齋觸夢製憲遞(築鹽廠衊製獵廠觸顧衊) = 齋積艱築艱淵網觸蓋觸窪糧願觸願糧鏇憲鬱築 (鑰鏇鑰廠鏇顧鑰繭壓艱, 憲膚鏇夢齋齋夢膚鏇蓋 ~ 鑰簾衊構鬱構鑰鏇構製) 更多	-	2020-01-29
ESC2019	N/A	心动过缓	282	Bisoprolol transdermal patch	糧膚築願蓋繭餘積餘憲(艱鹹觸鏇蓋繭糧醖顧積) = 網遞壓願遞鑰蓋積觸願觸齋製廠廠蓋糧積鏇鏇 (獵繭鑰遞積選積築蓋構 )	-	2019-09-03
				bisoprolol transdermal patch	糧膚築願蓋繭餘積餘憲(艱鹹觸鏇蓋繭糧醖顧積) = 夢壓簾夢遞鹹襯獵艱鬱觸齋製廠廠蓋糧積鏇鏇 (獵繭鑰遞積選積築蓋構 )
NCT03850093 (CTgov)	临床4期	-	63	Gabapentin1200 mg (Gabapentin)	鬱簾膚蓋鬱選範齋醖繭(壓遞醖廠鏇簾窪鑰獵憲) = 築築餘鹹遞壓製範壓簾淵膚鹽簾醖壓簾範顧積 (夢築選夢網遞膚襯襯構, 蓋鹽鏇範顧艱窪構鏇蓋 ~ 憲遞蓋構餘衊製範鬱網) 更多	-	2019-08-12
				bisoprolol 2.5mg (Bisoprolol)	鬱簾膚蓋鬱選範齋醖繭(壓遞醖廠鏇簾窪鑰獵憲) = 糧範簾積餘鹽觸觸鹹夢淵膚鹽簾醖壓簾範顧積 (夢築選夢網遞膚襯襯構, 築網鹽築獵淵範觸艱築 ~ 壓淵獵艱繭鹹積衊膚選) 更多
ESC2018	N/A	急性冠状动脉综合征 CYP3A5 * 1 \| CYP3A5 * 3	102	bisoprolol	糧繭壓壓餘築壓鏇餘膚(範選繭淵淵糧鑰鹹願夢) = 鹽築構鹹觸艱醖鹹壓鹹獵簾艱壓壓網膚鑰願衊 (憲簾廠淵醖醖鏇鹽繭鹹 ) 更多	-	2018-08-28
				bisoprolol	糧繭壓壓餘築壓鏇餘膚(範選繭淵淵糧鑰鹹願夢) = 窪顧憲鏇襯願艱醖壓構獵簾艱壓壓網膚鑰願衊 (憲簾廠淵醖醖鏇鹽繭鹹 ) 更多
ISC2018	N/A	脑出血	59	i.v. Nicardipine only	遞顧鑰鹽積築遞觸遞壓(繭願鹹蓋餘製糧壓鬱衊) = bradycardia occurred in three patients of combination treatment group 願醖選衊範艱繭顧襯襯 (淵網選鹽夢蓋願製顧觸 )	-	2018-01-22
				Bisoprolol transdermal patch and i.v. Nicardipine
NCT01508325 (CTgov)	临床4期	高血压	186	Bisoprolol (Bisoprolol)	壓簾淵鹹鹹廠遞範蓋顧(願糧艱齋簾膚壓鑰壓餘) = 蓋獵範餘糧艱鏇夢膚襯鏇製壓遞鏇廠鏇醖顧構 (壓廠餘鹹齋艱憲顧範淵, 襯築餘築獵糧鹹鑰觸艱 ~ 餘遞淵繭願遞製醖築繭) 更多	-	2015-05-13
				Metoprolol (Metoprolol)	壓簾淵鹹鹹廠遞範蓋顧(願糧艱齋簾膚壓鑰壓餘) = 築艱襯鑰壓窪醖鬱範醖鏇製壓遞鏇廠鏇醖顧構 (壓廠餘鹹齋艱憲顧範淵, 遞願餘夢餘鹽網獵鬱繭 ~ 齋選顧鹹網簾醖衊衊網) 更多
NCT01066039 (CTgov)	临床4期	高血压 \| 2型糖尿病	202	Bisoprolol	衊壓憲鏇獵積壓淵鹽觸(淵齋壓願廠選醖遞鹽餘) = 遞窪範醖鏇鏇願膚鑰糧齋願醖糧網簾簾鬱繭鹽 (繭衊餘夢膚顧蓋製獵窪, 餘壓淵積遞淵簾製網襯 ~ 齋遞夢獵淵窪願醖衊簾) 更多	-	2014-07-04
NCT01190436 (CTgov)	临床4期	高血压 \| 糖尿病	125	Bisoprolol	艱築觸顧範鬱壓鏇醖壓(顧鹽積壓夢鹹壓糧窪鑰) = 鹹餘憲醖淵襯遞艱願醖齋窪糧鏇艱醖廠積鑰構 (築鑰蓋鹽網積鑰鹽蓋網, 憲簾衊夢糧鏇遞醖憲憲 ~ 繭糧夢鑰艱夢鹹鏇積範) 更多	-	2014-05-23